1. AB1070 Adverse events with short vs long-term pegloticase therapy in trials of refractory chronic gout. (23rd January 2014) Authors: Wolfson, M.; Rehrig, C.; Bahrt, K. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 699 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0355 Real World Risk of Infusion Reactions with Pegloticase Treatment: Findings from Post-Approval us Safety Data. (23rd January 2014) Authors: Malamet, R.; Howson, T.; Yeo, A.; Bahrt, K. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A703 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0376 Uric Acid Levels as a Biomarker of Efficacy and Safety in Patients Treated with Pegloticase: Lessons Learned from us Clinical Experience. (23rd January 2014) Authors: Bahrt, K.; Yeo, A.; Howson, T.; Ottery, F. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A711 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗